Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia
Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia
复制标题
免疫性血小板减少症患者 Th22 细胞的升高及其与 Th17 细胞的相关性。
DOI：
10.1016/j.humimm.2012.04.015
复制
发表时间：
2012-06-01
期刊：
影响因子：
2.7
通讯作者：
Hou, Ming
中科院分区：
文献类型：
--
作者：
Hu, Yu;Li, Haiyan;Hou, Ming
辅助性t细胞（Th） 22和Th17参与自身免疫性疾病的发病机制。然而，Th22细胞在免疫性血小板减少症（ITP）病理生理中的作用尚不清楚。流式细胞术检测ITP患者和健康对照的Th22、Th17和Th1细胞。采用酶联免疫吸附试验（ELISA）检测血浆白细胞介素22 （IL-22）水平。采用定量逆转录聚合酶链反应（RT-PCR）检测信号转导和转录激活因子3 （STAT-3）和转录因子rar相关器官受体C （RORC）信使RNA （mRNA）的表达。ITP患者Th22细胞、Th17细胞、Th1细胞和血浆11-22均显著高于健康对照组。此外，Th22细胞与ITP患者血浆IL-22、Th17和Th1细胞水平呈正相关。STAT-3和RORC转录因子均显著上调。此外，自身抗体阴性的ITP患者Th22细胞的百分比高于自身抗体阳性的患者。我们的研究结果表明Th22细胞可能在ITP中起作用，因此，阻断IL-22可能是ITP的合理治疗策略。(C) 2012年美国组织相容性和免疫遗传学学会。Elsevier Inc.出版。版权所有。
T-helper (Th) 22 and Th17 cells are implicated in the pathogenesis of autoimmune diseases. However, the role of Th22 cells in the pathophysiology of immune thrombocytopenia (ITP) remains unclear. Th22, Th17 and Th1 cells in both ITP patients and healthy controls were examined by flow cytometry. Plasma interleukin-22 (IL-22) level was measured by enzyme linked immunosorbent assay (ELISA). Signal transducers and activators of transcription 3 (STAT-3) and transcription factor RAR-related organ receptor C (RORC) messenger RNA (mRNA) expressions were examined by quantitative reverse transcription polymerase chain reaction (RT-PCR). Th22 cells, Th17 cells, Th1 cells and plasma 11-22 were significantly higher in ITP patients than in healthy controls. Moreover, Th22 cells showed a positive correlation with the levels of plasma IL-22 as well as Th17 and Th1 cells in ITP patients. Significant up-regulations of both STAT-3 and RORC transcription factors were also observed. Additionally, the percentage of Th22 cells was higher in autoantibody-negative ITP patients than in autoantibody-positive patients. Our results demonstrate a possible role of Th22 cells in ITP, and thus, the blockade of IL-22 may be a reasonable therapeutic strategy for ITP. (C) 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.